| Download a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Apotex is Canada's largest domestic pharmaceutical manufacturer. This report
provides an insight into the company, reviewing its current business structure
and activities.
Apotex Inc. is the largest Canadian-owned pharmaceutical company. Founded with
two employees in 1974, it now employs over 6,000 people; 5,300 of them are
based in Canada, and the company has over 1,800 scientific staff. In Canada,
the company has operations in Brantford, Calgary, Etobicoke, Mississauga,
Montreal, Richmond Hill, Toronto, Vancouver, Windsor, and Winnipeg.
Additionally, Apotex has subsidiaries, joint ventures or licensing agreements
in effect in countries as diverse as China, Costa Rica, the Czech Republic,
France, Italy, Mexico, New Zealand, and Russia.
In Canada, Apotex has the following subsidiaries:
- Apotex Inc
- Novex Pharma
- TorPharm
- Accucaps
- Apotex Pharmachem
- Cangene
- Apotex Fermentation Inc.
This report provides information on the company's active product lines and
ANDA approvals, along with a review of major developments, such as M&A
activity, strategic alliances and litigation. The company's most recent
quarterly and annual financial results are illustrated with comparative
figures, charts and a detailed review of the data which allows you to track
the company's progress.
TABLE OF CONTENTS
- EXECUTIVE SUMMARY
- INTRODUCTION
- PRODUCTS
- Apotex ANDA Approvals, 2002-06
- Novex Pharma ANDA Approvals, 2002-05
- TorPharm ANDA Approvals, 2002-05
- Recent product approvals
- Diltiazem hydrochloride
- Clopidogrel
- Zonisamide
- Ofloxacin otic
- Leflunomide tablets
- Fosinopril
- Haloperidol
- Desmopressin acetate nasal spray
- FINANCIAL RESULTS
- Cangene
- Cangene Financial Results, 2000-04 (C$000s)
- MAJOR DEVELOPMENTS
- Apotex opens new R&D facility, expands other plants
- Mergers, acquisitions and agreements
- Akorn and Apotex sign ophthalmics
- Orchid Chemicals & Pharmaceuticals
- BioGeneriX
- Litigation
- Amlodipine
- Ketorolac
- Plavix
- Court favours Alpharma's gabapentin exclusivity
- CONTACT DETAILS
|
